CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 35 enrolled
Drug / intervention
Capivasertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04439123
NCT04439123Phase 2Active
CompareCT.gov

MATCH Treatment Subprotocol Y: AZD5363 in Patients With Tumors With AKT Mutations

National Cancer Institute (NCI)·interventional·Posted Jun 19, 2020·Updated May 6, 2026

In Brief

A Phase 2 clinical trial evaluating Capivasertib for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 35 participants across 1 site.

Detailed Summary

This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth. Researchers hope to learn if AZD5363 will shrink this type of cancer or stop its growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
20172018201920202021202220232024202520262027
First PostedJun 19, 2020
Enrollment StartMay 31, 2016
Primary CompletionNov 8, 2019
Study CompletionMar 31, 2027
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.0 years ago

Interventions

Capivasertibdrug

Given PO